title: Therapeutics for postexposure treatment of Ebola virus infection.
abstract: The current Ebola virus disease (EVD) outbreak in West Africa is the largest with over 5100 deaths in four West African countries as of 14 November 2014. EVD has high case-fatality rates but no licensed treatment or vaccine is yet available. Several vaccine candidates that protected nonhuman primates are not yet available for clinical use. Slow development of vaccine-stimulated immunity, sporadic nature and fast progression of EVD underlines the need for the development of effective postexposure therapeutic drugs. WHO encouraged the use of untested drugs for EVD to curb the fast-spreading outbreak. Here, we summarize therapeutics for EVD including monoclonal antibody-based therapy and inhibitors of viral replication including our recently developed small-molecule inhibitors of VP30 dephosphorylation.
authors.affiliation: Department of Microbiology, Howard University, Washington, DC 20059, USA.
authors.forename: Marina
authors.initials: M
authors.lastname: Jerebtsova
authors.affiliation: Department of Microbiology, Howard University, Washington, DC 20059, USA ; Center for Sickle Cell Disease, Howard University, Washington, DC 20059, USA ; Department of Medicine, Howard University, Washington, DC 20059, USA ; Department of Pharmacology, Howard University, Washington, DC 20059, USA.
authors.forename: Sergei
authors.initials: S
authors.lastname: Nekhai
keywords: 1E7-03; Ebola virus; antibody therapy; postexposure drugs